Strategic highlights: Aegon announces ambition to become a leading US life insurance and retirement group Aegon to move its head office and legal seat to the US and be renamed Transamerica Inc. at completion of transition, which Aegon aims to conclude by January 1, 2028 Aegon Asset Management to focus on growing third-party revenues and improving efficiency Continued focus on profitable growth in Aegon’s International business Strategic review of Aegon UK, evaluating all options, including divestmentFinancial highlights:Achieving all financial targets for 2025 Further execution upon Aegon’s strategy to reduce capital employed in Financial Assets through a reinsurance transaction on part of its SGUL block, reducing mortality and policyholder behavior risk and capital employed by USD 0.3 billion. Negative impact on RBC ratio neutralized...

Press release – Regulated InformationIeper, Belgium – 10 December 2025, 07.00 hrs CET – Melexis NV (Euronext Brussels: MELE) (“Melexis”) announces a new share buy-back program. The share buy-back program initiated by Melexis NV on 11 December 2024 will expire today 10 December 2025. Melexis’ Board of Directors has decided to initiate a new share buy-back program of its outstanding common stock for up to an additional 850,000 shares for an amount of up to EUR 50 million. This follows the shareholders’ authorization granted in November 2023. The share buy-back program is scheduled to run from 11 December 2025 until 10 December 2026. Pursuant to the shareholders’ authorization purchases will be effected at a price which will comply with the legal requirements, but which will in any case not be more than 10% below the lowest...

(2025-12-10) Kitron is hosting a Capital Markets Presentation today to update investors on the company’s financial and commercial targets and ambitions. Reflecting accelerating defence demand and expanded capacity, Kitron is updating and extending its medium-term ambitions. Over the coming year, the company expects to approach its previously communicated revenue target of EUR 1 billion. Kitron now outlines the way forward to EUR 1.5 billion in revenue. Kitron’s strategy calls for this growth to be combined with an EBIT margin above 9 per cent and a return on operating capital above 25 per cent. “Europe is entering an investment supercycle in defence, and manufacturing and electronics have become strategic bottlenecks. Without a secure, high-reliability manufacturing and supply chain, no country can deliver modern platforms at the...

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 9,142,857 shares of its common stock at a price to the public of $17.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 2,285,714 shares of common stock at a price of $17.49 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.01 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants are to be sold by Denali Therapeutics. In addition, Denali Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,714,285 shares of its common stock. Denali Therapeutics expects to receive total gross...

WATERTOWN, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the pricing of its underwritten public offering of $602.0 million of shares of its common stock. Kymera is selling 7,000,000 shares of common stock in the offering, which are being sold at a public offering price of $86.00 per share. In addition, Kymera has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The gross proceeds to Kymera from the offering are expected to be approximately $602.0 million, before deducting underwriting discounts and commissions...

FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the pricing of its upsized underwritten public offering of 16,250,000 shares of its common stock at a public offering price of $40.00 per share, before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Terns, are expected to be $650 million, excluding any exercise of the underwriters’ option to purchase additional shares. Terns has granted the underwriters a 30-day option to purchase up to an additional 2,437,500 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected...

CALGARY, Alberta, Dec. 09, 2025 (GLOBE NEWSWIRE) — Canacol Energy Ltd. (TSX: CNE) (OTCID: CNNEQ) (BVC: CNEC) (“Canacol” or the “Company”) announces that it has entered into an agreement with an ad hoc group of holders of the Company’s 5.75% senior unsecured notes due 2028 (the “DIP Credit Agreement”) for debtor-in-possession financing (the “DIP Financing”), comprised of a U.S.$45 million delayed-draw new-money term loan (the “Term Loan Tranche”) with capacity to obtain additional commitments to issue up to U.S.$22 million in letters of credit to renew and/or replace certain existing letters of credit (the “LC Tranche”). The DIP Financing will bear customary DIP interest and fees, will mature on June 30, 2026 (with a three-month extension option subject to conditions), and, subject to court approval, will be secured by a court-ordered...

SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the pricing of its upsized underwritten public offering of 8,461,538 American depositary shares (ADSs), each representing three ordinary shares, at a price to the public of $65.00 per ADS and pre-funded warrants to purchase 1,538,462 ADSs at a price to the public of $64.9999 per pre-funded warrant. All of the securities in the offering are being sold by Structure Therapeutics. The gross proceeds to Structure Therapeutics from the offering are expected to be approximately $650 million, before deducting underwriting discounts and commissions and offering expenses. In addition,...

This production start follows the recent arrival of multiple full sets of knockdown components — nearly 3,000 parts per vehicle — required for building the first batch of complete pre-production FX Super One vehicles which, once assembled, will be used for testing, marketing and other planning activities in the U.S.This production milestone marks the second vehicle model to come out of the Hanford facility, named “FF aiFactory California,” along with the Company’s FF 91 2.0 that is also assembled there.LOS ANGELES, Dec. 09, 2025 (GLOBE NEWSWIRE) — Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global shared intelligent electric mobility ecosystem company, today announced that it has launched the start of assembly production of the FX Super...

CAMBRIDGE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), announced today the pricing of its previously announced underwritten public offering of 15,789,475 of its ordinary shares at a price to the public of $19.00 per ordinary share, and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 2,631,578 ordinary shares at an offering price of $18.9999 per pre-funded warrant, which represents the per share offering price for the ordinary shares less the $0.0001 per share exercise price for each pre-funded warrant. Gross proceeds to Wave Life Sciences from the offering are expected to be approximately $350 million,...